natgillin/translations-raw huggingface dataset:
478 of the enrolled patients (32%) were defined as having a severe disease (CDAI score > 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1). 
Pri 478 zajetih bolnikih (32%) je bila bolezen opredeljena kot huda (seštevek CDAI > 300 ter sočasno zdravljenje s kortikosteroidom in//ali imunosupresivom), kar ustreza populaciji, opredeljeni pri indikacijah (glejte poglavje 4.1).
• Please make sure you also have a list of all your other medicines with you at any visit to a health care professional. 
• Poskrbite, da boste na vsak pregled pri zdravniku prinesli spisek vseh drugih zdravil, ki jih uporabljate.
• If you have multiple sclerosis, your doctor will decide if you should receive Trudexa. 
• Če imate multiplo sklerozo, bo zdravnik presodil, ali lahko dobivate Trudexo.
After proper training in injection technique, patients may self-inject with Trudexa if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si Trudexo lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
If a patient receiving Trudexa shows prolonged/atypical symptoms/signs of infections or general deterioration, prevalent opportunistic conditions must be considered. 
Če se pri bolniku, ki dobiva Trudexo, pojavijo dolgotrajni oz. atipični simptomi ali znaki okužbe ali pa splošno poslabšanje, je treba pomisliti na prevalentne oportunistične bolezni.
Results from the Short Form Health Survey (SF 36) for all doses/schedules of Trudexa in all four studies support these findings, with statistically significant physical component summary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40 mg every other week dose. 
Te izsledke podpirajo rezultati SF 36 (Short Form Health Survey) za vse odmerke/sheme Trudexe v vseh štirih raziskavah, s statistično značilnim seštevkom PCS (Physical Component Summary) in statistično značilnima seštevkoma za področje bolečin in vitalnosti za odmerek 40 mg vsak drugi teden.
• The needle cover of the syringe contains natural rubber (latex). 
• Pokrovček igle na brizgi vsebuje naravno gumo (lateks).
No studies have been conducted that include patients with a history of malignancy or that continue treatment in patients who develop malignancy while receiving Trudexa. 
Študij, ki bi vključevale bolnike z anamnezo malignoma ali v katerih bi nadaljevali zdravljenje pri bolnikih, ki so razvili malignom med prejemanjem Trudexe, ni bilo.
The infections consisted primarily of upper respiratory tract infections, bronchitis and urinary tract infections. 
Pri okužbah je šlo predvsem za okužbe zgornjih dihal, bronhitis in okužbe sečil.
**p < 0.01, Trudexa versus placebo 
**p < 0,01, Trudexa v prim.
• Do NOT shake the vial. 
• Viale NE STRESAJTE.
• If you are about to undergo surgery or dental procedures please inform your doctor that you are taking Trudexa. 
• Če boste imeli kirurški poseg ali poseg na zobeh, prosimo, povejte svojemu zdravniku, da jemljete Trudexo.
Take one dose tray containing a pre-filled pen of Trudexa from the refrigerator. 
Vzemite enoodmerni ovitek z napolnjenim injekcijskim peresnikom Trudexa iz hladilnika.
Liver Enzyme Elevations 
Zvišanje jetrnih encimov
• Some vaccines should not be given while receiving Trudexa. 
• Med zdravljenjem s Trudexo se ne sme uporabljati nekaterih cepiv.
The following instructions explain how to inject Trudexa. 
Spodnja navodila pojasnjujejo, kako injicirati Trudexo.
The conduct of these tests should be recorded on your Patient Alert Card. 
Izvedbo teh preiskav je treba zabeležiti na opozorilni izkaznici.
Carcinogenicity studies, and standard assessment of fertility and postnatal toxicity, were not performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and the development of neutralizing antibodies in rodents. 
Z adalimumabom niso bile narejene raziskave kancerogenosti in standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkrižno reaktivnostjo z glodalskim TNF, in zaradi nastanka nevtralizirajočih protiteles pri glodalcih.
In post-marketing experience from January 2003, predominately in patients with rheumatoid arthritis, the reported rate of malignancies other than lymphomas and non-melanoma skin cancers is approximately 1.7 per 1000 patient years. 
V obdobju pomarketinške uporabe od januarja 2003, pretežno pri bolnikih z revmatoidnim artritisom, je bil zabeleženi delež malignomov (razen limfomov in nemelanomskih kožnih rakov) približno 1,7 na 1000 bolnik-let.
Trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Trudexo je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljne zdravljenje z metotreksatom ni primerno.
Trudexa has not been studied in children or in patients with hepatic or renal impairment. 
Trudexa ni raziskana pri otrocih in bolnikih z okvaro jeter ali ledvic.
You will see a yellow indicator move into the windows during the injection. 
Med injiciranjem boste videli pomikanje rumenega kazalnika v okence.
Among patients who were not in response at week 4, 43% of Trudexa maintenance patients responded by week 12 compared to 30% of placebo maintenance patients. 
Med bolniki, ki so bili 4. teden brez odziva, se je do 12. tedna odzvalo 43% tistih, ki so vzdrževalno dobivali Trudexo, in 30% tistih, ki so vzdrževalno dobivali placebo.
The symptoms described above can be signs of the below listed side effects, which have been observed with Trudexa: 
Opisani simptomi so lahko znaki naslednjih neželenih učinkov, ugotovljenih med uporabo Trudexe:
CLASSIC I and GAIN induction of remission and response rates are presented in Table 9. 
Indukcijo remisije in deleže odziva v študijah CLASSIC I in GAIN prikazuje tabela 9.
In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality due to congestive heart failure have been observed. 
V klinični raziskavi z drugim antagonistom TNF so opažali poslabšanje kongestivnega srčnega popuščanja in večjo umrljivost zaradi kongestivnega srčnega popuščanja.
• lower respiratory tract infections (such as bronchitis, pneumonia); 
• okužbe spodnjih dihal (npr. bronhitis, pljučnica);
Gently tap the syringe to make any bubbles rise to the top of the syringe near the needle. 
Obzirno potrkajte po brizgi, da se bodo mehurčki dvignili na vrh brizge, blizu igle.
3) Injecting Trudexa 
3) Injiciranje Trudexe
• If you are allergic (hypersensitive) to adalimumab or any of the other ingredients of Trudexa. 
• če ste alergični na (preobčutljivi za) za adalimumab ali katerokoli sestavino zdravila Trudexa.
The white needle sleeve will move down over the needle and lock into place over the needle tip. 
Bel tulec igle se bo pomaknil navzdol prek igle in se bo zaskočil nad njeno konico.
In patients with Crohn's disease, adalimumab antibodies were identified in 7/269 subjects (2.6%) treated with adalimumab. 
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 oseb (2,6%), ki so bile zdravljene z adalimumabom.
Trudexa can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs. 
Trudexo se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), steroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
The percent of Trudexa-treated patients achieving ACR 20, 50 and 70 responses was consistent across trials I, II and III. 
Odstotek bolnikov, zdravljenih s Trudexo, ki so dosegli odziv 20, 50 in 70 po ACR, se je v raziskavah I, II in III skladal.
Cases of worsening congestive heart failure have also been reported in patients receiving Trudexa. 
O primerih poslabšanja kongestivnega srčnega popuščanja so poročali tudi pri bolnikih, ki so prejemali Trudexo.
• Make sure that the plunger is fully inserted into the syringe. 
• Prepričajte se, da je bat do konca potisnjen v brizgo.
Trudexa 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy. 
Trudexo 40 mg vsak drugi teden so ocenili v dveh randomiziranih 24-tedenskih dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa - Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
If the needle is correctly lined up, you should feel a slight resistance and then a “pop” as the needle goes through the centre of the stopper. 
Če je igla pravilno naravnana, boste čutili rahel upor in potem "pok", ko igla predre osrednji del zamaška.
TNF-antagonists including Trudexa have been associated in rare cases with new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. 
Antagonisti tumorje nekrotizirajočega faktorja (TNF), s Trudexo vred, so bili v redkih primerih povezani s pojavom ali poslabšanjem kliničnih simptomov in/ali rentgenoloških znakov demielinizirajoče bolezni.
You should continue to inject Trudexa for as long as your doctor has told you. 
Trudexo je treba injicirati toliko časa, kolikor vam je naročil zdravnik.
Study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. 
Raziskava II je ocenila 544 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno.
In the larger study (VIII) with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with Trudexa compared to placebo. 
Rezultati obsežnejše študije (VIII) pri 315 bolnikih so pri bolnikih, ki so dobivali Trudexo, pokazali statistično značilno izboljšanje znakov in simptomov ankilozirajočega spondilitisa v primerjavi s placebom.
Population pharmacokinetic analyses with data from over 1300 RA patients revealed a trend toward higher apparent clearance of adalimumab with increasing body weight. 
Analize populacijske farmakokinetike s podatki za več kot 1300 bolnikov z revmatoidnim artritisom so pokazale trend k večjemu navideznemu očistku adalimumaba z večanjem telesne teže.
Physicians should exercise caution when considering the use of Trudexa in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo Trudexe je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with Trudexa. 
Bolnike je treba pred, med in po zdravljenju s Trudexo natančno kontrolirati glede okužb, vključno s tuberkulozo.
Trudexa Mark your calendar with the stickers provided to remind you of the date for your next dose. 
Trudexa S priloženimi nalepkami si na koledarju označite datum, ko morate vzeti naslednji odmerek.
Alternatively, if a patient has stopped Trudexa and signs and symptoms of disease recur, Trudexa may be re-administered. 
Če bolnik neha uporabljati Trudexo, pa se znaki in simptomi bolezni ponovijo, je mogoče Trudexo znova uvesti.
Rare necrotising fasciitis, viral meningitis, diverticulitis 
redki nekrotizirajoči faciitis, virusni meningitis, divertikulitis
• Look at the expiry date on the vial. 
• Preverite datum izteka roka uporabnosti na viali.
In a study of 64 patients with rheumatoid arthritis that were treated with Trudexa, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-and B cells and NK-cells, monocyte/macrophages, and neutrophils. 
V raziskavi 64 bolnikov z revmatoidnim artritisom, zdravljenih s Trudexo, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.
Patients treated with Trudexa usually experienced improvement in haematological signs of chronic inflammation. 
S Trudexo zdravljenim bolnikom so se ponavadi izboljšali hematološki znaki kroničnega vnetja.
• You should not be treated with Trudexa if you have a severe infection. 
• Trudexe ne smete dobiti, če ste zboleli s katero od hudih okužb.
Trudexa is intended for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 
Trudexa je namenjena za zdravljenje revmatoidnega artritisa, psoriatičnega artritisa in ankilozirajočega spondilitisa.
• With the needle still inserted in the vial, check the syringe for air bubbles. 
• Medtem ko je igla še vedno v viali, preverite, ali so v brizgi zračni mehurčki.
1 st injection: _______________________ Following injections: 
Datumi zdravljenja s Trudexo: 1. injekcija: _______________________ Naslednje injekcije:
Subjects (n = 215, 54.7%) who failed to achieve ASAS 20 at Weeks 12, or 16 or 20 received early escape open-label adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses. 
Preiskovanci (n = 215, 54,7%), ki 12. ali 16. ali 20. teden niso dosegli ASAS 20, so začeli v predčasni odprti fazi dobivati 40 mg adalimumaba vsak drugi teden subkutano, v poznejših statističnih analizah dvojno slepe faza pa so bili obravnavani kot neodzivni bolniki.
Patients who develop a new infection while undergoing treatment with Trudexa should be monitored closely. 
Bolnike, pri katerih se med zdravljenjem s Trudexo pojavi nova okužba, je treba natančno nadzirati.
Trudexa can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment. 
Trudexo je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
Respiratory, thoracic and mediastinal disorders interstitial lung disease, including pulmonary fibrosis 
Bolezni dihal, prsnega koša in mediastinalnega prostora intersticijska bolezen pljuč, vključno s pljučno fibrozo
Study IIa** 
Raziskava IIa**
Table 6: Radiographic Mean Changes at Week 52 in Study V 
Tabela 6: Povprečne rentgenografske spremembe po 52 tednih študije V
Treatment with Trudexa may result in the formation of autoimmune antibodies. 
Zdravljenje s Trudexo lahko povzroči nastanek avtoimunskih protiteles.
Prescribers should exercise caution in considering the use of Trudexa in patients with pre-existing or recent-onset central nervous system demyelinating disorders. 
Pri odločanju za uporabo Trudexe pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega živčevja je potrebna previdnost.
What Trudexa is and what it is used for Before you use Trudexa How to use Trudexa Possible side effects 5 How to store Trudexa Further information 
Kaj je zdravilo Trudexa in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Trudexa Kako uporabljati zdravilo Trudexa Možni neželeni učinki
The needle cover of the syringe contains natural rubber (latex). 
Pokrovček igle na brizgi vsebuje naravno gumo (lateks).
Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Trudexa administration. 
Po uporabi Trudexe se je zmanjšala tudi serumska raven matriksnih metaloproteinaz (MMP-1 in MMP-3), ki povzročajo remodeliranje tkiva, odgovorno za uničenje hrustanca.
In Study IV, the ACR 20 response of patients treated with Trudexa plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p < 0.001). 
V raziskavi IV je bil odziv 20 po ACR pri bolnikih, zdravljenih s Trudexo in standardno oskrbo, statistično značilno boljši kot pri bolnikih, zdravljenih s placebom in standardno oskrbo (p < 0,001).
Table 2 Undesirable Effects in Postmarketing Surveillance and Phase IV Clinical Studies 
Tabela 2 Neželeni učinki med postmarketinškim nadzorom in kliničnimi študijami IV. faze
There have been reports of serious and severe opportunistic infections associated with Trudexa therapy, for example pneumocystis carinii pneumonia, disseminated histoplasmosis, listeriosis and aspergillosis. 
Opisani so primeri resnih in hudih oportunističnih okužb, povezanih s terapijo s Trudexo, npr. pnevmocistična pljučnica, diseminirana histoplazmoza, listerioza in aspergiloza.
Psoriatic arthritis clinical trials: elevations in ALT were more common in psoriatic arthritis patients (Studies VI-VII) compared with patients in rheumatoid arthritis clinical studies. 
Klinična preskušanja pri psoriatičnem artritisu: Zvišanja ALT so bila pri bolnikih s psoriatičnim artritisom (študiji VI-VII) pogostejša kot pri bolnikih v kliničnih študijah pri revmatoidnem artritisu.
In the twelve controlled trials, the rate of infection was 1.49 per patient year in the Trudexa treated patients and 1.42 per patient year in the placebo and active control-treated patients. 
V dvanajstih kontroliranih preskušanjih je bil delež okužb 1,49 na bolnik-leto med bolniki, ki so dobivali Trudexo, in 1,42 na bolnik-leto med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
Erosion score JSNd score amethotrexate b95% confidence intervals for the differences in change scores between methotrexate and Trudexa. 
Ocena erozij Ocena ZSŠd ametotreksat b95% intervali zaupanja za razlike v spremembi ocen med metotreksatom in Trudexo cna podlagi analize rangov dzožitev sklepne špranje
In rheumatoid arthritis, methotrexate is continued while using Trudexa. 
Pri revmatoidnem artritisu se uporaba metotreksata med uporabo Trudexe nadaljuje.
Furthermore, there is an increased background lymphoma risk in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. 
Poleg tega je pri bolnikih z revmatoidnim artritisom z dolgotrajno, zelo aktivno vnetno boleznijo zvečano osnovno tveganje za limfome, kar komplicira oceno tveganja.
Each pack contains 1 vial with an empty sterile syringe and 2 alcohol pads. 
Eno pakiranje vsebuje 1 vialo s prazno sterilno injekcijsko brizgo in 2 alkoholna zloženca.
Study VI with 24 week duration, treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50% were taking methotrexate. 
V njej so zdravili 313 odraslih, ki se niso ustrezno odzvali na terapijo z nesteroidnimi protivnetnimi zdravili; približno 50% od teh je jemalo metotreksat.
Therapy continued beyond 12 weeks did not result in significantly more responses (see section 
Zdravljenje prek 12. tedna ni prineslo značilno več odzivov (glejte poglavje 4.2).
A rapid decrease in CRP levels was also observed in patients with Crohn's disease. 
Pri pacientih s Crohnovo boleznijo so opazili tudi naglo znižanje koncentracij CRP.
Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. 
Dokazano je, da Trudexa upočasni napredovanje rentgenografsko merjene prizadetosti sklepov in izboljša telesno funkcijo, kadar se uporablja v kombinaciji z metotreksatom.
• Do not put either of the caps back on the pre-filled pen. 
• Ne enega ne drugega pokrovčka ne natikajte nazaj na napolnjeni injekcijski peresnik.
Like all medicines, Trudexa can have side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi Trudexa neželene učinke , ki pa se ne pojavijo pri vseh bolnikih.
Study VI 
Študija VI
This study evaluated the efficacy of Trudexa 40 mg every other week/methotrexate combination therapy, Trudexa 40 mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104 weeks. 
Ta študija je ocenila učinkovitost treh shem (kombinirana terapija s Trudexo 40 mg vsak drugi teden/metotreksatom, monoterapija s Trudexo 40 mg vsak drugi teden in monoterapija z metotreksatom) za zmanjšanje znakov in simptomov ter hitrosti napredovanja sklepne okvare pri revmatoidnem artritisu v obdobju 104 tednov.
A patient who requires surgery while on Trudexa should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem s Trudexo potrebuje operacijo, je treba natančno nadzirati glede okužb in ustrezno ukrepati.
• asthma, shortness of breath; 
• astma, hitra zadihanost;
Concurrent administration of TNF-antagonists and anakinra 
Sočasna uporaba antagonistov TNF in anakinre
NA NA 4.5% 23.2% a Study I at 24 weeks, Study II at 26 weeks , and Study III at 24 and 52 weeks b 40 mg Trudexa administered every other week c MTX = methotrexate 
NP 4,5% 23,2% a Raziskava I po 24 tednih, raziskava II po 26 tednih in raziskava III po 24 in 52 tednih b 40 mg Trudexe vsak drugi teden c MTX = metotreksat
In Studies I-IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. 
V raziskavah I-IV so se v primerjavi s placebom po 24 oz. 26 tednih izboljšali vsi posamezni elementi meril odziva po ACR (število bolečih in oteklih sklepov, zdravnikova in bolnikova ocena aktivnosti bolezni in bolečin, vrednost indeksa invalidnosti (HAQ) in vrednost CRP (mg/dl)).
Trudexa, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, Studies VI and VII. 
Uporabo Trudexe 40 mg vsak drugi teden so pri bolnikih z zmernim do hudim aktivnim psoriatičnim artritisom proučili v dveh s placebom kontroliranih študijah, študiji VI in študiji VII.
The serum adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and 80 mg every other week and every week subcutaneous dosing. 
Najnižje koncentracije adalimumaba v serumu v stanju dinamičnega ravnovesja so naraščale približno sorazmerno odmerku po 20, 40 in 80 mg vsak drugi teden in vsak teden subkutano.
When combining controlled portions of ten trials (I-IX and CHARM) and ongoing open label extension studies with a median duration of approximately 2. years including 4843 patients and over 13000 patient-years of therapy, the observed rate of malignancies, other than lymphoma and nonmelanoma skin cancers is approximately 13.6 per 1000 patient years. 
Če vzamemo skupaj kontrolirane dele desetih preskušanj (I-IX in CHARM) in potekajoče nadaljevalne študije z medianim trajanjem približno 2 leti s 4843 bolniki in prek 13000 bolnik-leti zdravljenja, je ugotovljeni delež malignomov (razen limfoma in nemelanomskih kožnih rakov) približno 13,6 na 1000 bolnik-let.